(Albany, US) DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2032” report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Recent Development in the Hereditary Angioedema Market
- In February 2020, BioCryst Pharmaceuticals announced that the US Food and Drug Administration (FDA) accepted and filed its new drug application (NDA) for the approval of berotralstat (BCX7353) for the prevention of Hereditary Angioedema (HAE) attacks.
- KVD900 received Fast Track designation from the US FDA, supporting the Company’s belief in the high level of unmet need in HAE and providing a potentially expedited path to drug approval.
- BioMarin expects to complete preclinical work with BMN 331 in the year 2020 and in anticipation of a possible clinical trial in early 2022.
- C1 esterase inhibitor (human) manufactured by ViroPharma Biologics, Inc. was approved in June 2018 for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).
Request for Sample Report: https://www.delveinsight.com/sample-request/hereditary-angioedema-market
Key benefits of the Hereditary Angioedema Market report:
- The study provides a detailed review of Hereditary Angioedema, including its causes, signs and symptoms, pathophysiology, diagnosis, and current treatments.
- Study of the 7MM has offered comprehensive insight into the epidemiology and management of Hereditary Angioedema.
- Furthermore, an all-inclusive description of both present and emerging Hereditary Angioedema treatments is offered, as well as an analysis of future therapies that will have an influence on the current treatment landscape.
- The research includes a full evaluation of the Hereditary Angioedema market, both historical and anticipated, as well as drug outreach in the 7MM population.
- By understanding the trends defining and driving the worldwide Hereditary Angioedema market, the study gives you an advantage when formulating business plans.
Hereditary Angioedema Overview
Hereditary Angioedema is a disorder marked by recurring bouts of significant swelling (angioedema). Limbs, face, intestinal tract, and airway are the most affected parts of the body. Minor trauma or stress may precipitate an episode, although edema frequently happens in the absence of a specific cause. Intestinal episodes result in acute stomach discomfort, nausea, and vomiting. Swelling in the airway can hinder breathing and perhaps result in a life-threatening blockage. There are three forms of Hereditary Angioedema: I, II, and III, which may be identified by their underlying causes and blood levels of a protein called C1 inhibitor.
The symptoms of Hereditary Angioedema includes:
- Angioedema
- Abdominal pain
- Ascites
- Facial edema
- Intestinal edema
Laboratory analysis of blood samples, or genetic samples, are required to establish a Hereditary Angioedema diagnosis. There are three specific blood tests used to confirm Hereditary Angioedema Type I or II, which are:
- C1-inhibitor quantitative (antigenic)
- C1-inhibitor functional
- C4
Hereditary Angioedema Market
The report’s Hereditary Angioedema market outlook assists in developing a detailed understanding of historic, current, and forecasted Hereditary Angioedema market trends by analyzing the impact of current Hereditary Angioedema therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This section examines the Hereditary Angioedema market trend of each marketed drug and late stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing market need, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, market impact, and key opinion leaders’ perspectives. Hereditary Angioedema market statistics are supplied with pertinent tables and graphs to provide a comprehensive picture of the market at a glance. According to DelveInsight, the Hereditary Angioedema market in 7MM is expected to undergo significant change between 2019 and 2032.
Learn more by requesting for sample @ Hereditary Angioedema Market Landscape
Hereditary Angioedema Key Companies
- Takeda
- Shire/Takeda
- CSL Behring
- Pharming Group
- BioCryst Pharmaceuticals
- Ionis Pharmaceuticals
- KalVista Pharmaceuticals
Hereditary Angioedema Pipeline
- Takhzyro
- Firazyr
- Cinryze
- Kalbitor
- Haegarda
- Berinert
- Ruconest
- BCX7353
- IONIS-PKK-LRx
- KVD900
- CSL312
Table of Contents
- Key Insights
- Executive Summary of Hereditary Angioedema
- Competitive Intelligence Analysis for Hereditary Angioedema
- Hereditary Angioedema: Market Overview at a Glance
- Hereditary Angioedema: Disease Background and Overview
- Patient Journey
- Hereditary Angioedema Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Hereditary Angioedema Unmet Needs
- Key Endpoints of Hereditary Angioedema Treatment
- Hereditary Angioedema Marketed Products
- Hereditary Angioedema Emerging Therapies
- Hereditary Angioedema: Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview of Hereditary Angioedema
- KOL Views
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Other Reports:
DelveInsight’s “Menorrhalgia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Menorrhalgia, historical and forecasted epidemiology as well as the Menorrhalgia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hereditary-angioedema-market